The Shell Clock: How Much Time Does Hadassit Bio Really Have to Bring in a New Activity?

Two clocks, not one

The main article already established that Hadassit Bio is no longer being read as a life-sciences holding company. It is now being read as a public shell with a small cash balance, a shareholder bridge loan, and a legal option around Cell Cure. This follow-up isolates the issue the main piece only compressed: how much time that shell really has left before it must bring in a new activity, rather than merely talk about one.

The core point is that the regulatory clock and the economic clock are no longer moving at the same speed. At the rulebook level, the securities face deletion from trading if the company does not return to the main list by May 6, 2028. At the cash level, the filing states explicitly that as of the approval date, March 12, 2026, liquid resources are not sufficient for 12 months. Sitting between those two is the shareholder bridge loan granted on December 1, 2025 for 14 months, meaning until February 1, 2027, or earlier if proceeds arrive from the Cell Cure process.

This is no longer a theoretical debate about how much time remains under TASE preservation-list rules. It is a practical question of whether the company can solve its funding problem and its shell-status problem inside roughly the same window. Put differently, the filing gives it until 2028 on paper, but materially less than that in cash.

That table is the heart of the continuation thesis. Once the two shorter clocks sit about a year ahead of the longer one, the date that really matters is no longer May 2028.

Why 2025 bought time, but did not solve the problem

To understand how much time was actually purchased, 2025 has to be read through an all-in cash-flexibility lens, not through the net-loss line. This is not a business with normalized cash generation. It is a shell funding itself through asset sales and bridge financing.

In 2025 the company used NIS 1.729 million of cash in operating activities. That was the main cash drain. Against that, it received NIS 1.339 million from investing activities after selling the remaining Enlivex shares and paying tax, and another NIS 1.097 million from financing activities, almost entirely the shareholder loan. Cash and cash equivalents therefore rose from NIS 869 thousand to NIS 1.485 million at year-end, but that increase did not come from improving business economics. It came from liquidating the last tradable asset and replacing it with a liability.

That chart shows why the higher cash balance can mislead on a quick read. The company did not end the year with more cash because something in the business improved. It ended the year with more cash because it sold what remained of the old liquidity source, Enlivex, and added a new liquidity source, a shareholder loan. That is not time created by operations. It is time purchased from elsewhere.

There is a second layer here. The loan came in at a nominal NIS 1.142 million, equivalent to USD 350 thousand, but was initially recognized at fair value of NIS 1.050 million using a 7.5% market rate. The NIS 92 thousand gap was credited to equity. Even the accounting treatment says the same thing: this was not ordinary commercial financing. It supports liquidity, but it also underlines that the company is no longer funded by an operating business. It is funded by shareholder tolerance.

Why the shell clock is shorter than it looks

The easiest mistake in reading a shell story is to treat the preservation list as the only problem. But exiting this status is built on two cumulative conditions, not one. The company must first cease being a shell company, and then also satisfy the listing standards of a new company, including equity, public-holdings value, and minimum distribution.

The first condition is already difficult. TASE says a shell company needs a real business activity that generates, or is expected to generate, revenues in the ordinary course of business, and not merely finance income, while 80% or more of its assets must not consist of cash, deposits, or passive financial assets. Hadassit Bio’s filing is not brushing up against that test. It almost exemplifies it.

At the end of 2025, 96% of the balance sheet consisted of cash and cash equivalents. Revenue was just NIS 63 thousand, of which NIS 24 thousand was finance income and NIS 39 thousand was fair-value change. The company has no bank credit, no revenue-generating real activity, and states explicitly that as of the report date it has no real business activity that generates or is expected to generate ordinary-course revenue. So this is not a debate over whether the company is close to leaving shell status. It remains squarely inside the definition.

There is a biotech carve-out in the rules for a technology or biotech company that invested at least NIS 400 thousand gross in R&D during the previous 12 months, but the current filing provides no visible path through that exception. If anything, it points the other way. The company says its limited financial resources prevent it from participating in portfolio financing rounds or making new investments. So the sector-specific route, at least on this evidence set, does not look ready-made.

The second condition is just as hard. Even if a new activity is found for merger, the current balance sheet starts from a weak point. Equity attributable to shareholders fell from a positive NIS 1.616 million at the end of 2024 to a deficit of NIS 17 thousand at the end of 2025. Working capital fell from a positive NIS 2.037 million to a deficit of NIS 17 thousand.

That chart sharpens the paradox. Cash went up, but equity and working capital collapsed to roughly zero. So bringing in a new activity will require more than finding a target. The company will also need to rebuild enough capital to get through a listing test.

The bridge loan adds time, but also changes the order of priorities

The natural instinct is to read the December 2025 loan as breathing room, and that is true. But the agreement does something else as well. It reshuffles the order in which future proceeds would be used.

Final maturity is 14 months from drawdown, but there is also an earlier trigger, 7 business days from receipt of proceeds in an amount equal to the loan from the Cell Cure legal process. That matters analytically: if Cell Cure starts producing cash, the first effect may not be greater flexibility for the shell. The first effect may be repayment of the bridge.

That is easy to miss. On first read, the legal process and the shareholder loan look like two separate sources of time. In practice they are connected. The loan funds the period during which the company is trying to bring in a new activity and pursue the Cell Cure case, but if Cell Cure turns into cash, the bridge can disappear quickly. So even a partial legal success would not necessarily leave Hadassit Bio with a free cash cushion for rebuilding the company. Part of it could go straight back to the financier.

That also helps explain why management is not treating the Cell Cure process as a standalone rescue plan. The filing says explicitly that it is examining the introduction of a new activity and may also turn to major shareholders for further funding. The right reading is that the company itself is not relying on one salvation path.

So how much time is really left

If one stays only with the formal language, the answer could be “until 2028.” That is legally correct, but economically weak. The filing itself gives a different answer.

At the accounting level, the company says that as of the accounts approval date, March 12, 2026, cash and cash equivalents stood at NIS 1.199 million, and that liquid resources are not sufficient for 12 months. That is already a direct statement that the funding window does not run to March 2027. At the burn-rate level, negative operating cash flow of NIS 1.729 million in 2025 represents an annual pace larger than the cash the company had on hand at approval date. That suggests that even before any increase in deal or litigation costs, the comfortable window is shorter than a year.

At the contract level, the bridge loan is due by February 1, 2027, or earlier. At the classification level, even a successful deal would not be enough unless it comes with capital and renewed listing compliance. So the practical answer to “how much time is really left” is not “until 2028.” The practical answer is that the decision window sits in 2026 and into early 2027.

That is exactly why this shell looks riskier than the preservation-list clock alone suggests. The company is not really running a 48-month race. It is running a race of a few quarters to bring in content, capital, and bridge funding at the same time.

What has to happen to stop the clock

The company needs three things in close sequence.

First, it needs a new activity with real business economics, not another passive holding and not just a story. Without that, shell status does not end.

Second, it needs capital. A deficit of NIS 17 thousand in both equity and working capital is not dramatic in absolute terms, but it shows that the shell is entering this race without a cushion.

Third, it needs funding to carry the period between identifying a target and closing the transaction. Without that bridge, even a suitable activity loses value because the company would negotiate from a weaker position.

That is also the key counter-thesis to this analysis. It is possible that controlling shareholders continue to provide funding as needed, that a new activity is found faster than expected, and that Cell Cure eventually produces value. But the 2025 filing does not support treating any of those three as resources already in hand. For now they remain conditions that still need to materialize.

Conclusion

The message of the 2025 filing is sharper than it first appears. Hadassit Bio does not have only a shell clock. It has a liquidity clock, a bridge-funding clock, and a listing-compliance clock. All three converge well before May 2028.

Current thesis: Hadassit Bio’s real time horizon is now measured in quarters, not in years.

2025 did not solve the shell problem. It merely deferred it by selling the last tradable asset and replacing it with shareholder bridge funding. From here, every month that passes without a new activity and without additional capital brings the company closer to the point where even an existing public shell no longer offers enough practical flexibility.

What the market may miss is that the hoped-for merger, if it comes, will have to do more than one job. It will not only need to bring in an operating activity. It will also need to end shell status, rebuild the equity layer, and arrive before the temporary funding runs out. That is no longer a distant optionality story. It is a timing story.